This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.
Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137–45.
Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105:4215–22.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419–25.
Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124:3029–31.
Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96:1280–6.
Boisjoly J, Bouchard P, Cohen S, Ahmad I, Bambace NM, Bernard L, et al. Impact of carmustine (BCNU) substitution for bendamustine in the conditioning regimen prior to autologous hematopoietic cell transplantation for the treatment of lymphoma. Blood. 2017;130:2022.
Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant. 2016;51:319–21.
Isidori A, Christofides A, Visani G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma. 2016;57:2499–509.
Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers. Am J Hematol. 2018;93:729–35.
Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C. et al.A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma. 2017;22:1–8.
Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol. 2017;96:421–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
DV, ASG, JMC, KJS, LHS, and DWS receive research funding from Roche to support the BC Cancer Centre for Lymphoid Cancer database. DV: Lundbeck honoraria and consultancy (advisory boards). YAM: Honoraria and consultancy from JAZZ, Celgene, and Amgen. DS: Pfizer and Novartis consultancy and honoraria. ASG: Honoraria and advisory boards from both Lundbeck and Seattle Genetics. AI: Lundbeck honoraria and consultancy, TEVA consultancy.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Tsang, E.S., Villa, D., Loscocco, F. et al. High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 54, 481–484 (2019). https://doi.org/10.1038/s41409-018-0328-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0328-9
This article is cited by
-
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT
Bone Marrow Transplantation (2020)
-
Antineoplastics
Reactions Weekly (2020)